comparemela.com

Latest Breaking News On - Natco pharma ltd - Page 40 : comparemela.com

ICICI Securities, Natco Pharma among 6 stocks with bullish MACD crossover

ETMarkets has identified six Indian companies that have recently experienced a bullish MACD crossover, as identified by its advanced screener. A bullish crossover is when the MACD line, which is the 12-day exponential moving average of the stock price minus the 26-day exponential moving average, crosses above the signal line, being the nine-day exponential moving average of the MACD line. The companies are DCM Shriram, ICICI Securities, Natco Pharma, Harsha Engineers International, Shanthi Gears and Bharti Airtel. Investors seeking opportunities in the stock market can use the technical indicator to assess potential future price appreciation.

Kansai Nerolac, Godrej Industries, Macrotech Developers among 6 stocks with bullish harami cross pattern

The Bullish Harami Cross candlestick pattern has been spotted in the technical charts of several prominent stocks, indicating a possible trend reversal and presenting an opportunity for investors to explore. These include The Fertilisers And Chemicals Travancore, Kansai Nerolac Paints, Godrej Industries, Macrotech Developers, Jindal Stainless, and Natco Pharma. However, investors should conduct further research and analyze fundamental factors before making investment decisions. The Bullish Harami Cross pattern can serve as a valuable tool in identifying potential investment opportunities.

Natco gets nod for Tipiracil Hydrochloride, Trifluridine for US market

Hyderabad-Based Natco Pharma Returns To Profit In Q4 As Business Grows In Us, Canada

In the March quarter, total revenue stood at Rs 898 crore, up 50.5 percent against Rs 596.8 crore in the year-ago period. Shares of Natco Pharma Ltd ended at Rs 635.10, up by Rs 5.75, or 0.91 percent on the BSE.

Natco Pharma Ltd consolidated Q4 FY2023 PAT jumps to Rs 275 8 crores

The Board of Directors of Natco Pharma Limited, at its meeting held today have approved the financial results of the company for the period ended March 31, 2023 - Q4FY23 and FY2023.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.